Preview

 Пульмонология

Расширенный поиск

Хроническая обструктивная болезнь легких: профилактика обострений. Клинические рекомендации Американской коллегии торакальных врачей и Канадского торакального общества (часть 1 я)

https://doi.org/10.18093/0869-0189-2016-26-2-153-179

Полный текст:

Аннотация

Хроническая обструктивная болезнь легких (ХОБЛ) является одной из основных причин заболеваемости и летальности в США и в ми ре. Обострения ХОБЛ (периодическое усиление кашля, одышки и продукции мокроты) вносят серьезный вклад в снижение легочной функции, качества жизни, повышение потребности в неотложной помощи и госпитализациях, а также в стоимость лечения больных. В последние десятилетия выполнены исследования, по результатам которых существенно углубилось понимание патогенеза ХОБЛ и расширились терапевтические возможности. Накоплен также большой объем публикаций по предотвращению обострений ХОБЛ. Материалы и методы. Для разъяснения важности предотвращения обострений ХОБЛ Американской коллегией торакальных врачей (American College of Chest Physicians – CHEST) и Канадским торакальным обществом (Canadian Thoracic Society Guideline – CTS) раз работаны совместные Клинические рекомендации, в которых описан существующий сегодня подход к профилактике обострений ХОБЛ. Выделены 3 основных клинических проблемы профилактики обострений ХОБЛ на основе принципов PICO (Population, Intervention, Comparator, Outcome – Популяция, Вмешательства, Сравнение, Исходы) – немедикаментозное лечение, ингаляционная и пероральная терапия. Использована общепринятая система отбора соответствующих клинических исследований и оценки класса ре комендаций. Результаты. Особенность Клинических рекомендаций по профилактике обострений ХОБЛ заключается не только в их те матике, но также в том, что они стали первым результатом сотрудничества 2 крупных торакальных обществ Северной Америки. Наме рение Надзорного комитета по созданию клинических рекомендаций CHEST в сотрудничестве с Клинической ассамблеей по ХОБЛ CTS заключается в том, чтобы на основе систематического обзора и критической оценки опубликованной литературы, сделанных кли ническими экспертами и исследователями в области ХОБЛ, разработать клинические рекомендации с целью помочь клиницистам в ве дении пациентов с этим заболеванием. Заключение. В данных Рекомендациях содержится современный доказательный анализ опубли кованных результатов рандомизированных контролируемых исследований по профилактике обострений ХОБЛ. 

Об авторе

статья Редакционная

Россия


Список литературы

1. Global Initiative for Chronic Obstructive Lung Disease. Global strategy for the diagnosis, management and prevention of chronic obstructive pulmonary disease. Updated 2103. Global Initiative for Chronic Obstructive Lung Disease website. HYPERLINK "http://www.goldcopd" http://www.goldcopd. org/uploads/users/files/GOLD_Report_2013_Feb20.pdf. Accessed May 15, 2014.

2. Brusasco V. Reducing cholinergic constriction: the major reversible mechanism in COPD. Eur. Respir. Rev. 2006; 15 (99): 32–36.

3. Cooper CB. Airflow obstruction and exercise. Respir. Med. 2009; 103 (3): 325–334.

4. Public Health Agency of Canada. Chronic obstructive pulmonary disease (COPD). Public Health Agency of Canada website. http://www.phac-aspc.gc.ca/cd-mc/crd-mrc/copd-mpoc-eng.php. Accessed June 28, 2012.

5. Centers for Disease Control and Prevention; National Center for Health Statistics. Deaths: final data for 2009. Natl. Vital. Stat. Rep. 2012; 60 (3): 1–117.

6. Centers for Disease Control and Prevention; National Center for Health Statistics. National Health Interview Survey Raw Data, 1999–2011. Analysis performed by the American Lung Association Research and Healtheducation Division using SPSS and SUDAAN software. Atlanta GA: Centers for Disease Control and Prevention; 2011.

7. Mannino D.M., Homa D.M., Akinbami L.J. et al. Centers for Disease Control and Prevention. Chronic obstructive pulmonary disease surveillance – United States, 1971–2000. MMWR Surveill. Summ. 2002; 51 (6): 1–16.

8. Centers for Disease Control and Prevention; National Center for Health Statistics. National Hospital Discharge Survey Raw Data, 1999 – 2010. Analysis Performed by the American Lung Association Research and Healtheducation Division Using SPSS Soft ware. Atlanta GA: Centers for Disease Control and Prevention; 2010.

9. Confronting COPD in America, 2000. Schulman, Ronca and Bucuvalas, Inc. (SRBI); 2000. Funded by GlaxoSmithKline plc.

10. Mittmann N., Kuramoto L., Seung S.J. et al. The cost of moderate and severe COPD exacerbations to the Canadian healthcare system. Respir. Med. 2008; 102 (3): 413–421.

11. Chapman K.R., Bourbeau J., Rance L. The burden of COPD in Canada: results from the Confronting COPD survey. Respir. Med. 2003; 97 (Suppl. C): S23–S31.

12. Connors A.F. Jr, Dawson N.V., Thomas C. et al. Outcomes following acute exacerbation of severe chronic obstructive lung disease. The SUPPORT investigators (Study to Understand Prognoses and Preferences for Outcomes and Risks of Treatments). Am. J. Respir. Crit. Care Med. 1996; 154 (4): 959–967.

13. Seemungal T.A., Donaldson G.C., Paul E.A. et al. Effect of exacerbation on quality of life in patients with chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 1998; 157 (5): 1418–1422.

14. Miravitlles M., Murio C., Guerrero T. et al. Pharmacoeconomic evaluation of acute exacerbations of chronic bronchitis and COPD. Chest. 2002; 121 (5): 1449–1455.

15. Miravitlles M., Garcia-Polo C., Domenech A. et al. Clinical outcomes and cost analysis of exacerbations in chronic obstructive pulmonary disease. Lung. 2013; 191 (5): 523–530.

16. Wouters E.F. Economic analysis of the confronting COPD survey: an overview of results. Respir. Med. 2003; 97 (Suppl. C): S3–S14.

17. Celli B.R., MacNee W. ATS/ERS Task Force. Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper. Eur. Respir. J. 2004; 23 (6): 932–946.

18. Maltais F., Celli B., Casaburi R. et al. Aclidinium bromide improves exercise endurance and lung hyperinflation in patients with moderate to severe COPD. Respir. Med. 2011; 105 (4): 580–587.

19. Rodriguez-Roisin R. Toward a consensus definition for COPD exacerbations. Chest. 2000; 117 (5, Suppl. 2): 398S–401S.

20. Qaseem A., Wilt T.J., Weinberger S.E. et al. Diagnosis and management of stable chronic obstructive pulmonary disease: a clinical practice guideline update from the American College of Physicians, American College of Chest Physicians, American Thoracic Society, and European Respiratory Society. Ann. Intern. Med. 2011; 155 (3): 179–191.

21. Albert R.K., Connett J., Bailey W.C. et al. COPD Clinical Research Network. Azithromycin for prevention of exacerbations of COPD. N. Engl. J. Med. 2011; 365 (8): 689–698.

22. Calverley P., Pauwels R., Vestbo J. et al. Combined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease: a randomised controlled trial. Lancet. 2003; 361 (9356): 449–456.

23. Tashkin D.P., Celli B., Senn S. et al; UPLIFT Study Investigators. A 4-year trial of tiotropium in chronic obstructive pulmonary disease. N. Engl. J. Med. 2008; 359 (15): 1543–1554.

24. Lewis S.Z., Diekemper R., Ornelas J., Casey K.R. Methodologies for the development of CHEST guidelines and expert panel reports. Chest. 2014; 146 (1): 182–192.

25. Brouwers M.C., Kho M.E., Browman G.P. et al. AGREE II: advancing guideline development, reporting and evaluation in health care. CMAJ. 2010; 182 (18): E839–E842.

26. Diekemper R., Ireland B., Merz L. P154 development of the Documentation and Appraisal Review Tool (DART) for systematic reviews [poster]. Br. Med. J. Qual. Saf. 2013; 22: 61–62.

27. Higgins J.P.T., Altman D.G., Sterne J.A.C. et al. Chapter 8: assessing risk of bias in included studies. In: Higgins J.P.T., Green S, eds. Cochrane Handbook for Systematic Reviews of Interventions. Version 5.1.0 [updated March 2011]. London: The Cochrane Collaboration; 2011.

28. Downs S.H., Black N. The feasibility of creating a checklist for the assessment of the methodological quality both of randomised and non-randomised studies of health care interventions. J. Epidemiol. Community Health. 1998; 52 (6): 377–384.

29. Langer-Gould A., Popat R.A., Huang S.M. et al. Clinical and demographic predictors of long-term disability in patients with relapsing-remitting multiple sclerosis: a systematic review. Arch. Neurol. 2006; 63 (12): 1686–1691.

30. Aaron S.D., Fergusson D., Marks G.B. et al. Counting, analysing and reporting exacerbations of COPD in randomised controlled trials. Thorax. 2008; 63 (2): 122–128.

31. Balshem H., Helfand M., Schunemann H.J. et al. GRADE guidelines: 3. Rating the quality of evidence. J. Clin. Epidemiol. 2011; 64 (4): 401–406.

32. Guyatt G., Gutterman D., Baumann M.H. et al. Grading strength of recommendations and quality of evidence in clinical guidelines: report from an American College of Chest Physicians task force. Chest. 2006; 129 (1): 174–181.

33. Graham I.D., Logan J., Harrison M.B. et al. Lost in knowledge translation: time for a map? J. Contin. Educ. Health Prof. 2006; 26 (1): 13–24.

34. Bodenheimer T., Wagner E.H., Grumbach K. Improving primary care for patients with chronic illness. JAMA. 2002; 288 (14): 1775–1779.

35. Bodenheimer T., Wagner E.H., Grumbach K. Improving primary care for patients with chronic illness: the chronic care model, part 2. JAMA. 2002; 288 (15): 1909–1914.

36. Chronic obstructive pulmonary disease: management of chronic obstructive pulmonary disease in adults in primary and secondary care (partial update). National Institute for Health and Care Excellence website. HYPERLINK "http://guidance.nice.org.uk/CG101/Guidance/" http://guidance.nice.org.uk/CG101/Guidance/pdf/English. Accessed May 15, 2014.

37. O’Donnell D.E., Aaron S., Bourbeau J. et al. Canadian Thoracic Society recommendations for management of chronic obstructive pulmonary disease–2007 update. Can. Respir. J. 2007; 14 (Suppl. B): 5B–32B.

38. Disler R.T., Inglis S.C., Davidson P.M. Non-pharmacological management interventions for COPD: an overview of Cochrane systematic reviews (protocol). Cochrane Database Syst. Rev. 2013; (2): CD010384.

39. Kruis A.L., Smidt N., Assendelft W.J.J. et al. Integrated disease management interventions for patients with chronic obstructive pulmonary disease. Cochrane Database Syst. Rev. 2011; (10): CD009437.

40. Krumholz H.M., Currie P.M., Riegel B. et al. A taxonomy for disease management: a scientific statement from the American Heart Association Disease Management Taxonomy Writing Group. Circulation. 2006; 114 (13): 1432–1445.

41. Craig P., Dieppe P., Macintyre S. et al. Research Council Guidance. Developing and evaluating complex interventions: the new Medical Research Council guidance. Br. Mer. J. 2008; 337: a1655.

42. Petticrew M. When are complex interventions ‘complex’? When are simple interventions ‘simple’? Eur. J. Public. Health. 2011; 21 (4): 397–398.

43. Weightman A., Ellis S., Cullum A. et al. Grading Evidence and Recommendations for Public Health Interventions: Developing and Piloting a Framework. London: Health Development Agency; 2005.

44. Vaccines and immunizations. Centers for Disease Control and Prevention website. http://www.cdc.gov/vaccines/vpd-vac/pneumo. Accessed March 3, 2014.

45. Lee T.A., Weaver F.M., Weiss K.B. Impact of pneumococcal vaccination on pneumonia rates in patients with COPD and asthma. J. Gen. Intern. Med. 2007; 22 (1): 62–67.

46. Centers for Disease Control and Prevention; Advisory Committee on Immunization Practices. Updated recommendations for prevention of invasive pneumococcal disease among adults using 23-valent pneumococcal polysaccharide vaccine (PPSV23). Morb. Mortal. Wkly Rep. 2010; 59 (34): 1102–1106.

47. Bogaert D., van der Valk P., Ramdin R. et al. Host-pathogen interaction during pneumococcal infection in patients with chronic obstructive pulmonary disease. Infect. Immun. 2004; 72 (2): 818–823.

48. Patel I.S., Seemungal T.A.R., Wilks M. et al. Relationship between bacterial colonisation and the frequency, character, and severity of COPD exacerbations. Thorax. 2002; 57 (9): 759–764.

49. Sethi S., Evans N., Grant B.J.B., Murphy T.F. New strains of bacteria and exacerbations of chronic obstructive pulmonary disease. N. Engl. J. Med. 2002; 347 (7): 465–471.

50. Papi A., Bellettato C.M., Braccioni F. et al. Infections and airway inflammation in chronic obstructive pulmonary disease severe exacerbations. Am. J. Respir. Crit. Care Med. 2006; 173 (10): 1114–1121.

51. WHO recommendations for routine immunization summary tables. World Health Organization website. http://www.who.int/immunization/policy/immunization_tables/en. Accessed March 3, 2014.

52. Walters J.A., Smith S., Poole P. et al. Injectable vaccines for preventing pneumococcal infection in patients with chronic obstructive pulmonary disease. Cochrane Database Syst. Rev. 2010; (11): CD001390.

53. Dransfield M.T., Harnden S., Burton R.L. al. Long-term comparative immunogenicity of protein conjugate and free polysaccharide pneumococcal vaccines in chronic obstructive pulmonary disease. Clin. Infect. Dis. 2012; 55 (5): e35–e44.

54. Furumoto A., Ohkusa Y., Chen M. et al. Additive effect of pneumococcal vaccine and influenza vaccine on acute exacerbation in patients with chronic lung disease. Vaccine. 2008; 26 (33): 4284–4289.

55. Fiore A.E., Uyeki T.M., Broder K. et al. Prevention and control of influenza with vaccines: recommendations of the Advisory Committee on Immunization Practices (ACIP), 2010. MMWR Rec. Rep. 2010; 59 (RR-8): 1–62.

56. Centanni S., Pregliasco F., Bonfatti C. et al. Clinical efficacy of a vaccine-immunostimulant combination in the prevention of influenza in patients with chronic obstructive pulmonary disease and chronic asthma. J. Chemother. 1997; 9 (4): 273–278.

57. Monto A.S. Influenza: quantifying morbidity and mortality. Am. J. Med. 1987; 82 (6A): 20–25.

58. Poole P., Chacko E.E., Wood-Baker R., Cates C.J. Influenza vaccine for patients with chronic obstructive pulmonary disease. Cochrane Database Syst. Rev. 2006; (1): CD002733.

59. Howells C.H., Tyler L.E. Prophylactic use of influenza vaccine in patients with chronic bronchitis. A pilot trial. Lancet. 1961; 278 (7218): 1428–1432.

60. Wongsurakiat P., Maranetra K.N., Wasi C. et al. Acute respiratory illness in patients with COPD and the effectiveness of influenza vaccination: a randomized controlled study. Chest. 2004; 125 (6): 2011–2020.

61. Fletcher C., Peto R. The natural history of chronic airflow obstruction. Br. Med. J. 1977; 1 (6077): 1645–1648.

62. Hersh C.P., DeMeo D.L., Al-Ansari E. et al. Predictors of survival in severe, early onset COPD. Chest. 2004; 126 (5): 1443–1451.

63. Scanlon P.D., Connett J.E., Waller L.A. et al. Smoking cessation and lung function in mild-to-moderate chronic obstructive pulmonary disease. The Lung Health Study. Am. J. Respir. Crit. Care Med. 2000; 161 (2): 381–390.

64. Kanner R.E., Connett J.E., Williams D.E., Buist A.S. Effects of randomized assignment to a smoking cessation intervention and changes in smoking habits on respiratory symptoms in smokers with early chronic obstructive pulmonary disease: the Lung Health Study. Am. J. Med. 1999; 106 (4): 410–416.

65. Makris D., Moschandreas J., Damianaki A. et al. Exacerbations and lung function decline in COPD: new insights in current and ex-smokers. Respir. Med. 2007; 101 (6): 1305–1312.

66. Tashkin D., Kanner R., Bailey W. et al. Smoking cessation in patients with chronic obstructive pulmonary disease: a double-blind, placebo-controlled, randomised trial. Lancet. 2001; 357 (9268): 1571–1575.

67. Jimenez-Ruiz C.A., Masa F., Miravitlles M. et al. Smoking characteristics: diff erences in attitudes and dependence between healthy smokers and smokers with COPD. Chest. 2001; 119 (5): 1365–1370.

68. Strassmann R., Bausch B., Spaar A. et al. Smoking cessation interventions in COPD: a network metaanalysis of randomised trials. Eur. Respir. J. 2009; 34 (3): 634–640.

69. van der Meer R.M., Wagena E.J., Ostelo R.W. et al. Smoking cessation for chronic obstructive pulmonary disease. Cochrane Database Syst. Rev. 2003; (2): CD002999.

70. Tonnesen P., Carrozzi L., Fagerstrom K.O. et al. Smoking cessation in patients with respiratory diseases: a high priority, integral component of therapy. Eur. Respir. J. 2007; 29 (2): 390–417.

71. Au D.H., Bryson C.L., Chien J.W. et al. The effects of smoking cessation on the risk of chronic obstructive pulmonary disease exacerbations. J. Gen. Intern. Med. 2009; 24 (4): 457–463.

72. Christenhusz L.C., Prenger R., Pieterse M.E. et al. Cost-effectiveness of an intensive smoking cessation intervention for COPD outpatients. Nicotine Tob. Res. 2012; 14 (6): 657–663.

73. Borglykke A., Pisinger C., Jorgensen T., Ibsen H. The effectiveness of smoking cessation groups offered to hospitalised patients with symptoms of exacerbations of chronic obstructive pulmonary disease (COPD). Clin. Respir. J. 2008; 2 (3): 158–165.

74. Godtfredsen N.S., Vestbo J., Osler M., Prescott E. Risk of hospital admission for COPD following smoking cessation and reduction: a Danish population study. Thorax. 2002; 57 (11): 967–972.

75. Szabo E., Mao J.T., Lam S. et al. Chemoprevention of lung cancer: diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest. 2013; 143 (5, Suppl.): e40S–e60S.

76. Spruit M.A., Singh S.J., Garvey C. et al; ATS/ERS Task Force on Pulmonary Rehabilitation. An official American Thoracic Society / European Respiratory Society statement: key concepts and advances in pulmonary rehabilitation. Am. J. Respir. Crit. Care Med. 2013; 188 (8): e13–e64.

77. Marciniuk D.D., Brooks D., Butcher S. et al. Optimizing pulmonary rehabilitation in chronic obstructive pulmonary disease – practical issues: a Canadian Thoracic Society Clinical Practice Guideline. Can. Respir. J. 2010; 17 (4): 159–168.

78. Ries A.L., Bauldoff G.S., Carlin B.W. et al. Pulmonary rehabilitation: Joint ACCP/AACVPR evidence-based clinical practice guidelines. Chest. 2007; 131 (5, Suppl.): 4S–42S.

79. Lacasse Y., Goldstein R., Lasserson T.J., Martin S. Pulmonary rehabilitation for chronic obstructive pulmonary disease. Cochrane Database Syst. Rev. 2006; (4): CD003793.

80. Lacasse Y., Wong E., Guyatt G.H. et al. Meta-analysis of respiratory rehabilitation in chronic obstructive pulmonary disease. Lancet. 1996; 348 (9035): 1115–1119.

81. Nici L., ZuWallack R. An official American Thoracic Society workshop report: the integrated care of the COPD patient. Proc. Am. Thorac. Soc. 2012; 9 (1): 9–18.

82. Ko F.W., Dai D.L., Ngai J. et al. Effect of early pulmonary rehabilitation on health care utilization and health status in patients hospitalized with acute exacerbations of COPD. Respirology. 2011; 16 (4): 617–624.

83. Behnke M., Taube C., Kirsten D. et al. Home-based exercise is capable of preserving hospital-based improvements in severe chronic obstructive pulmonary disease. Respir. Med. 2000; 94 (12): 1184–1191.

84. Murphy N., Bell C., Costello R.W. Extending a home from hospital care programme for COPD exacerbations to include pulmonary rehabilitation. Respir. Med. 2005; 99 (10): 1297–1302.

85. Ringbaek T., Brondum E., Martinez G. et al. Long-term effects of 1-year maintenance training on physical functioning and health status in patients with COPD: a randomized controlled study. J. Cardiopulm. Rehabil. Prev. 2010; 30 (1): 47–52.

86. Roman M., Larraz C., Gуmez A. et al. Efficacy of pulmonary rehabilitation in patients with moderate chronic obstructive pulmonary disease: a randomized controlled trial. BMC Fam. Pract. 2013; 14: 21.

87. Man W.D., Polkey M.I., Donaldson N. et al. Community pulmonary rehabilitation after hospitalisation for acute exacerbations of chronic obstructive pulmonary disease: randomised controlled study. Br. Med. J. 2004; 329 (7476): 1209.

88. Seymour J.M., Moore L., Jolley C.J. et al. Outpatient pulmonary rehabilitation following acute exacerbations of COPD. Thorax. 2010; 65 (5): 423–428.

89. Boxall A.M., Barclay L., Sayers A., Caplan G.A. Managing chronic obstructive pulmonary disease in the community. A randomized controlled trial of home-based pulmonary rehabilitation for elderly housebound patients. J. Cardiopulm. Rehabil. 2005; 25 (6): 378–385.

90. Eaton T., Young P., Fergusson W. et al. Does early pulmonary rehabilitation reduce acute health-care utilization in COPD patients admitted with an exacerbation? A randomized controlled study. Respirology. 2009; 14 (2): 230–238.

91. Puhan M.A., Gimeno-Santos E., Scharplatz M. et al. Pulmonary rehabilitation following exacerbations of chronic obstructive pulmonary disease. Cochrane Database Syst. Rev. 2011; (10): CD005305.

92. Wagner E.H. Chronic disease management: what will it take to improve care for chronic illness? Eff. Clin. Pract. 1998; 1 (1): 2–4.

93. Case Management Society of America. What is a case manager? Case Management Society of America website. HYPERLINK "http://www.cmsa" http://www.cmsa.org/Home/CMSA/WhatisaCaseManager/tabid/224/Default.aspx. Accessed March 18, 2014.

94. Zwerink M., Brusse-Keizer M., van der Valk P.D. et al. Self management for patients with chronic obstructive pulmonary disease. Cochrane Database Syst. Rev. 2014; (3): CD002990.

95. Jarab A.S., Alqudah S.G., Khdour M. et al. Impact of pharmaceutical care on health outcomes in patients with COPD. Int. J. Clin. Pharmacol. 2012; 34 (1): 53–62.

96. Farrero E., Escarrabill J., Prats E. et al. Impact of a hospital-based home-care program on the management of COPD patients receiving long-term oxygen therapy. Chest. 2001; 119 (2): 364–369.

97. Lainscak M., Kadivec S., Kosnik M. et al. Discharge coordinator intervention prevents hospitalizations in patients with COPD: a randomized controlled trial. J. Am. Med. Dir. Assoc. 2013; 14 (6): 450.e1–450.e6.

98. Smith B.J., Appleton S.L., Bennett P.W. et al. The effect of a respiratory home nurse intervention in patients with chronic obstructive pulmonary disease (COPD). Aust. N. Z. J. Med. 1999; 29 (5): 718–725.

99. Soler J.J., Martinez-Garcia M.A., Roman P. et al. Effectiveness of a specific program for patients with chronic obstructive pulmonary disease and frequent exacerbations [in Spanish]. Arch. Bronconeumol. 2006; 42 (10): 501–508.

100. Gallefoss F. The effects of patient education in COPD in a 1-year follow-up randomised, controlled trial. Patient Educ. Couns. 2004; 52 (3): 259–266.

101. McGeoch G.R., Willsman K.J., Dowson C.A. et al. Self-management plans in the primary care of patients with chronic obstructive pulmonary disease. Respirology. 2006; 11 (5): 611–618.

102. Wakabayashi R., Motegi T., Yamada K. et al. Efficient integrated education for older patients with chronic obstructive pulmonary disease using the Lung Information Needs Questionnaire. Geriatr. Gerontol. Int. 2011; 11 (4): 422–430.

103. Wood-Baker R., McGlone S., Venn A., Walters E.H. Written action plans in chronic obstructive pulmonary disease increase appropriate treatment for acute exacerbations. Respirology. 2006; 11 (5): 619–626.

104. Bourbeau J., Julien M., Maltais F. et al. Chronic Obstructive Pulmonary Disease axis of the Respiratory Network Fonds de la Recherche en Santee du Quebec. Reduction of hospital utilization in patients with chronic obstructive pulmonary disease: a diseasespecific self-management intervention. Arch. Intern. Med. 2003; 163 (5): 585–591.

105. Casas A., Troosters T., Garcia-Aymerich J. et al. Integrated care prevents hospitalisations for exacerbations in COPD patients. Eur. Respir. J. 2006; 28 (1): 123–130.

106. Fan V.S., Gaziano J.M., Lew R. et al. A comprehensive care management program to prevent chronic obstructive pulmonary disease hospitalizations: a randomized, controlled trial. Ann. Intern. Med. 2012; 156 (10): 673–683.

107. Khdour M.R., Kidney J.C., Smyth B.M., McElnay J.C. Clinical pharmacy-led disease and medicine management programme for patients with COPD. Br.J. Clin. Pharmacol. 2009; 68 (4): 588–598.

108. Rea H., McAuley S., Stewart A. et al. A chronic disease management programme can reduce days in hospital for patients with chronic obstructive pulmonary disease. Intern. Med. J. 2004; 34 (11): 608–614.

109. Rice K.L., Dewan N., Bloomfield H.E. et al. Disease management program for chronic obstructive pulmonary disease: a randomized controlled trial. Am. J. Respir. Crit. Care Med. 2010; 182 (7): 890–896.

110. Trappenburg J.C., Monninkhof E.M., Bourbeau J. et al. Effect of an action plan with ongoing support by a case manager on exacerbation-related outcome in patients with COPD: a multicenter randomised controlled trial. Thorax. 2011; 66 (11): 977–984.

111. Walters J., Cameron-Tucker H., Wills K. et al. Effects of telephone health mentoring in community-recruited chronic obstructive pulmonary disease on self-management capacity, quality of life and psychological morbidity: a randomised controlled trial. Br. Med. J. Open. 2013; 3 (9): e003097.

112. Bischoff E.W., Akkermans R., Bourbeau J. et al. Comprehensive self management and routine monitoring in chronic obstructive pulmonary disease patients in general practice: randomised controlled trial. Br. Med. J. 2012; 345: e7642.

113. Coultas D., Frederick J., Barnett B. et al. A randomized trial of two types of nurse-assisted home care for patients with COPD. Chest. 2005; 128 (4): 2017–2024.

114. Gadoury M.A., Schwartzman K., Rouleau M. et al; Chronic Obstructive Pulmonary Disease axis of the Respiratory Health Network, Fonds de la recherche en sante du Quebec (FRSQ). Self-management reduces both shortand long-term hospitalisation in COPD. Eur. Respir. J. 2005; 26 (5): 853–857.

115. Hermiz O., Comino E., Marks G. et al. Randomised controlled trial of home based care of patients with chronic obstructive pulmonary disease. Br. Med. J. 2002; 325 (7370): 938.

116. Telemedicine: opportunities and developments in member states. Report on the second global survey on eHealth. World Health Organization website. http://www.who.int/goe/publications/goe_telemedicine_2010.pdf. Accessed March 13, 2014.

117. What is telemedicine? American Telemedicine Association website. http://www.americantelemed.org/about-telemedicine/what-is-telemedicine. Accessed March 13, 2014.

118. de Toledo P., Jimenez S., del Pozo F. et al. Telemedicine experience for chronic care in COPD. IEEE Trans. Inf. Technol. Biomed. 2006; 10 (3): 567–573.

119. Vitacca M., Bianchi L., Guerra A. et al. Tele-assistance in chronic respiratory failure patients: a randomised clinical trial. Eur. Respir. J. 2009; 33 (2): 411–418.

120. Wong K.W., Wong F.K., Chan M.F. Effects of nurse-initiated telephone follow-up on self-efficacy among patients with chronic obstructive pulmonary disease. J. Adv. Nurs. 2005; 49 (2): 210–222.

121. McLean S., Nurmatov U., Liu J.L. et al. Telehealthcare for chronic obstructive pulmonary disease. Cochrane Database Syst. Rev. 2011; (7): CD007718.

122. Antoniades N.C., Rochford P.D., Pretto J.J. et al. Pilot study of remote telemonitoring in COPD. Telemed. J. E. Health. 2012; 18 (8): 634–640.

123. Chau J.P., Lee D.T., Yu D.S. et al. A feasibility study to investigate the acceptability and potential effectiveness of a telecare service for older people with chronic obstructive pulmonary disease. Int. J. Med. Inform. 2012; 81 (10): 674–682.

124. Dinesen B., Haesum L.K., Soerensen N. et al. Using preventive home monitoring to reduce hospital admission rates and reduce costs: a case study of telehealth among chronic obstructive pulmonary disease patients. J. Telemed. Telecare. 2012; 18 (4): 221–225.

125. Gellis Z.D., Kenaley B., McGinty J. et al. Outcomes of a telehealth intervention for homebound older adults with heart or chronic respiratory failure: a randomized controlled trial. Gerontologist. 2012; 52 (4): 541–552.

126. Haesum L.K., Soerensen N., Dinesen B. et al. Cost-utility analysis of a telerehabilitation program: a case study of COPD patients. Telemed. J. E. Health. 2012; 18 (9): 688–692.

127. Halpin D.M., Laing-Morton T., Spedding S. et al. A randomized controlled trial of the effect of automated interactive calling combined with a health risk forecast on frequency and severity of exacerbations of COPD assessed clinically and using EXACT PRO. Prim. Care Respir. J. 2011; 20 (3): 324–331.

128. Henderson C., Knapp M., Fernandez J.L. et al. Cost effectiveness of telehealth for patients with long term conditions (Whole Systems Demonstrator telehealth questionnaire study): nested economic evaluation in a pragmatic, cluster randomised controlled trial. Br. Med. J. 2013; 346: f1035.

129. Holland A. Telehealth reduces hospital admission rates in patients with COPD. J. Physiother. 2013; 59 (2): 129.

130. Jуdar-Sanchez F., Ortega F., Parra C. et al. Implementation of a telehealth programme for patients with severe chronic obstructive pulmonary disease treated with long-term oxygen therapy. J. Telemed. Telecare. 2013; 19 (1): 11–17.

131. Koff P.B., Jones R.H., Cashman J.M. et al. Proactive integrated care improves quality of life in patients with COPD. Eur. Respir. J. 2009; 33 (5): 1031–1038.

132. Lewis K.E., Annandale J.A., Warm D.L. et al. Does home telemonitoring after pulmonary rehabilitation reduce healthcare use in optimized COPD? A pilot randomized trial. COPD. 2010; 7 (1): 44–50.

133. Pare G., Poba-Nzaou P., Sicotte C. et al. Comparing the costs of home telemonitoring and usual care of chronic obstructive pulmonary disease patients: a randomized controlled trial. Eur. Res. Telemed. 2013; 2 (2): 35–47.

134. Pedone C., Chiurco D., Scarlata S., Incalzi R.A. Efficacy of multiparametric telemonitoring on respiratory outcomes in elderly people with COPD: a randomized controlled trial. BMC Health Serv. Res. 2013; 13: 82.

135. Pinnock H., Hanley J., Lewis S. et al. The impact of a telemetric chronic obstructive pulmonary disease monitoring service: randomised controlled trial with economic evaluation and nested qualitative study. Prim. Care Respir. J. 2009; 18 (3): 233–235.

136. Shany T., Hession M., Pryce D. et al. Home telecare study for patients with chronic lung disease in the Sydney West Area Health Service. Stud. Health Technol. Inform. 2010; 161: 139–148.

137. Sorknaes A.D., Madsen H., Hallas J. et al. Nurse tele-consultations with discharged COPD patients reduce early readmissions-an interventional study. Clin. Respir. J. 2011; 5 (1): 26–34.

138. Steventon A., Bardsley M., Billings J. et al. Effect of telehealth on use of secondary care and mortality: findings from the Whole System Demonstrator cluster randomised trial. Br. Med. J. 2012; 344: e3874.

139. Venter A., Burns R., Hefford M., Ehrenberg N. Results of a telehealth-enabled chronic care management service to support people with long-term conditions at home. J. Telemed. Telecare. 2012; 18 (3): 172–175.

140. Wootton R. Twenty years of telemedicine in chronic disease management – an evidence synthesis. J. Telemed. Telecare. 2012; 18 (4): 211–220.


Для цитирования:


Хроническая обструктивная болезнь легких: профилактика обострений. Клинические рекомендации Американской коллегии торакальных врачей и Канадского торакального общества (часть 1 я).  Пульмонология. 2016;26(2):153-179. https://doi.org/10.18093/0869-0189-2016-26-2-153-179

For citation:


Therapeutic strategy to prevent acute exacerbations of chronic obstructive pulmonary disease: clinical guidelines of American College of Chest Physicians and Canadian Thoracic Society Guideline (Part 1). Russian Pulmonology. 2016;26(2):153-179. (In Russ.) https://doi.org/10.18093/0869-0189-2016-26-2-153-179

Просмотров: 692


ISSN 0869-0189 (Print)
ISSN 2541-9617 (Online)